CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

Author:

Herrmann Nathan1,Ismail Zahinoor2,Collins Rhonda3,Desmarais Philippe4,Goodarzi Zahra5,Henri‐Bhargava Alexandre6,Iaboni Andrea78,Kirkham Julia9,Massoud Fadi10,Moser Andrea11,Silvius James12,Watt Jennifer13,Seitz Dallas2

Affiliation:

1. Department of Psychiatry Sunnybrook Health Sciences Centre University of Toronto Toronto Ontario Canada

2. Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Cumming School of Medicine; Hotchkiss Brain Institute and O'Brien Institute of Public Health University of Calgary, Calgary, Alberta, Canada

3. Department of Family Medicine McMaster University Chief Medical Officer, Revera Inc Hamilton Ontario Canada

4. Department of Medicine Division of Geriatrics and Department of Neurosciences Centre de Recherche du Centre Hospitalier de l'Université de Montréal Montréal Québec Canada

5. Division of Geriatrics, Department of Medicine, Cumming School of Medicine; Hotchkiss Brain Institute; O'Brien Institute of Public Health University of Calgary Calgary Canada

6. Division of Neurology, Faculty of Medicine University of British Columbia; Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada

7. Department of Psychiatry University of Toronto Toronto Ontario Canada

8. Kite Research Institute, Toronto Rehabilitation Institute University Health Network Toronto Ontario Canada

9. Department of Psychiatry Cumming School of Medicine, University of Calgary

10. Department of Medicine University of Sherbrooke Sherbrooke Quebec Canada

11. Department of Family and Community Medicine University of Toronto, Associate Medical Director, Jewish Home for the Aged, Baycrest Toronto Ontario Canada

12. Division of Geriatric Medicine, Department of Medicine, Cumming School of Medicine University of Calgary, Calgary, Alberta, Canada

13. Division of Geriatric Medicine Department of Medicine, University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference44 articles.

1. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

2. Management of mild to moderate Alzheimer's disease and dementia

3. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

4. Donepezil for dementia due to Alzheimer's disease;Birks JS;Cochrane Database Syst Rev,2018

5. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta‐analysis;Glinz D;Swiss Med Wkly,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3